<DOC>
	<DOCNO>NCT00003993</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Interleukin-2 may stimulate person 's white blood cell kill cancer cell . Combining chemotherapy interleukin-2 may kill cancer cell . PURPOSE : This phase I trial study side effect best dose interleukin-2 give together bryostatin 1 treat patient refractory solid tumor lymphoma .</brief_summary>
	<brief_title>Bryostatin 1 Interleukin-2 Treating Patients With Refractory Solid Tumors Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety side effect bryostatin 1 interleukin-2 patient refractory solid tumor lymphomas . - Determine maximum tolerate dose interleukin-2 bryostatin 1 patient . - Determine whether bryostatin 1 interleukin-2 increase expression recognition costimulatory molecule human monocyte ability act antigen present cell . - Assess anti-tumor response patient treat regimen . OUTLINE : This dose escalation study interleukin-2 . Patients receive bryostatin 1 IV 24 hour day 1 8 , interleukin-2 subcutaneously day 1-5 day 8-12 . Treatment continue every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos interleukin-2 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : A total 18-24 patient accrue study less 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Bryostatin 1</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven solid tumor lymphoma curable surgery , radiotherapy , standard chemotherapy , curative therapy exist Prostate cancer patient must follow : Tumor progression follow blockade testicular adrenal androgen Serum testosterone castrate range ( le 20 ng/mL ) At least 3 month since prior suramin therapy At least 4 week since prior flutamide antiandrogen medication evidence response treatment Luprolide continue prior orchiectomy No prior concurrent brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 0 1 Life expectancy : At least 3 month Hematopoietic : WBC least 3,500/mm^3 OR Granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 8 g/dL Hepatic : Hepatitis B surface antigen negative PT great 14 second PTT great 35 second Bilirubin great 1.5 mg/dL unless due Gilbert 's disease SGOT SGPT great 2.5 time upper limit normal ( ULN ) Alkaline phosphatase great 2.5 time ULN Albumin least 2.5 g/dL Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 50 mL/min Corrected calcium least 8.0 mg/dL , great 10.7 mg/dL Cardiovascular : No prior myocardial infarction , coronary artery disease ( CAD ) , congestive heart failure , second third degree AV block , cardiac arrhythmia require treatment No evidence CAD EKG Pulmonary : FEV11 least 70 % predict DLCO least 60 % predict Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative At least 1 week since active infection require antibiotic No medical psychiatric condition would preclude study No prior concurrent seizure disorder control medication PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior interleukin2 At least 4 week since prior biologic therapy solid tumor lymphomas Chemotherapy : See Disease Characteristics At least 4 week since prior bryostatin 1 At least 4 week since prior chemotherapy solid tumor lymphomas Endocrine therapy : See Disease Characteristics At least 4 week since prior endocrine therapy solid tumor lymphomas No absolute requirement corticosteroid Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy solid tumor lymphomas Surgery : See Disease Characteristics At least 4 week since prior surgery solid tumor lymphomas Other : No absolute requirement nonsteroidal antiinflammatory drug H2 blocker</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>small intestine lymphoma</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
	<keyword>intraocular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>